While not all of the differences observed in these Western blot and mass spectrometry experiments showed statistically significant changes, there was an apparent trend of higher LRRK2 signal in the G2019S groups (NMC and LRRK2 PD) in both the Western blot and mass spectrometry data. This evidence concerns the gene LRRK2 and Parkinson disease.